Pharmacy Times September 2, 2024
Robert Walker discusses the updated COVID-19 vaccines targeting the new JN.1 lineage of the virus and the challenges of addressing vaccine hesitancy to protect individuals and communities.
Robert Walker, MD, senior vice president, chief medical officer, and interim head of research and development at Novavax, explains that the COVID-19 pandemic has entered a new phase, with a different family of the virus, the JN.1 lineage, now circulating in the US. Similar to the annual process for updating influenza vaccines, new COVID-19 vaccines have been developed to target this emerging strain. However, Walker notes that vaccination rates have declined, with only 21 to 22% of people receiving the shots last season. He attributes this to vaccine hesitancy, as some are tired...
Today's Sponsors
Today's Sponsor